Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies

BACKGROUND: The prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin’s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treatment of these cancers, AFM11 is a tetravalent, bispecific hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Topp, Max, Dlugosz-Danecka, Monika, Skotnicki, Aleksander B., Salogub, Galina, Viardot, Andreas, Klein, Andreas K., Hess, Georg, Michel, Christian S., Grosicki, Sebastian, Gural, Alex, Schwarz, Sylvia E., Pietzko, Kerstin, Gärtner, Ulrike, Strassz, András, Alland, Leila, Mayer, Jiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808944/
https://www.ncbi.nlm.nih.gov/pubmed/36597128
http://dx.doi.org/10.1186/s13063-022-06982-7

Ejemplares similares

Ejemplares similares